- The Navacim Technology Platform
- Development Pipeline Overview
- Scientific Publications
- The Board of Directors
- Dr. Phil Coggins, President & CEO
- Dr. Pere Santamaria, Founder & CSO
- Scientific Advisors
- Parvus Wins The $125,000 Alberta nanoVenture Prize (video)
The Gateway To Our Technology & Company
The Parvus technology platform, and the Navacim therapeutic candidates that it produces, sit on very solid scientific foundations and like many great scientific discoveries both the candidates and the platform lie at the confluence of talented people, great ideas, meticulous planning, and expert execution. The technology section of our site describes in detail how a cascade of discovery led to a breakthrough in our understanding of autoimmunity and to a radically different and long sought after way to approach therapy.
To some, our story may look like serendipity, but in fact, Nature has thrown back a curtain on the almost unfathomable complexity of the immune system and its workings, and presented us with a new way to tackle autoimmune disease. Our starting point is Type 1 Diabetes (T1D) but we believe that the implications of our discoveries go far beyond a single disease — welcome to Parvus Central.
This is the hub of our website and the gateway to our company. We invite you to discover more about our technology and follow along in the coming months as we take our first therapeutic candidate, NavacimTD, from the laboratory to the clinic as an entirely new treatment for diabetes.
Parvus Central is also the place where we will detail our success in attracting investment and development partners to ensure that the full potential of the Navacim platform reaches the broadest possible patient population in the shortest possible time. We aim to keep the information on our website as up to date and dynamic as the platform which it showcases — so come back often as we do our level best to improve the lives of patients with autoimmune disease.
Privately Held, Generously Supported
Parvus is a privately held corporation based in Calgary, Alberta, Canada and has been financed to date by its existing shareholders, and by very generous technology commercialization assistance from granting agencies and research charities in Canada and the United States.
Notable amongst our supporters are the Juvenile Diabetes Research Foundation International (JDRF), The Government of Canada (NRC/IRAP, NSERC, CIHR) , The Government of Alberta (AHFMR), and University Technologies International LP.
Disease-Specific, Compositionally Alike
The Parvus technology platform encompasses a significant part of current medical practice, and consequently, the partnership potential is enormous and partners essential. We are actively seeking pharmaceutical and biotechnology industry partners to join with us in bringing Navacims to the clinic in the most efficient and cost-effective way possible.
Navacims, by their nature and design, are exquisitely disease specific and yet the differences in their chemical composition can appear almost insignificant at first glance. We think that these characteristics, and what we reasonably expect to be very standardized manufacturing procedures, ancillary assays, and modes of testing, make Navacims very attractive therapeutic candidates for partnership. We welcome expressions of interest from potential partners.